Medtronic plc is a sleepy Dividend Aristocrat with the potential for dividend growth to reaccelerate in the next 12 to 24 months. MDT beat the analyst consensus for revenue and non-GAAP EPS in Q4 2026, with the highest annual revenue growth in 10 years. Medtronic sports an A S&P credit rating with a stable outlook.